Apos®, a Non-Invasive Knee Treatment, Proven to Delay Surgery According to a Real-World Study
Retrieved on:
Wednesday, September 7, 2022
FACP, Osteoarthritis, Knee pain, Muscle, Heritage, Pain, OA, Obesity, HPN, FRCP, Brain, Time, Ageing, Gait, Senior, Population health, Quality of life, Multimedia, Depression, Disability, Health, Patient, Movement, Prevalence, FDA, TKR, Gait analysis, Population Health Management, Contract, Health insurance, Medical device, Medical imaging, Apos
Secondary outcomes of the study, at one year, showed a significant reduction in pain and disability, an increase in quality of life, and improved gait patterns.
Key Points:
- Secondary outcomes of the study, at one year, showed a significant reduction in pain and disability, an increase in quality of life, and improved gait patterns.
- "As the lead researcher on this study, we are impressed at how the clinical results of our study reinforce Apos' place in the knee osteoarthritis care pathway by offering patients a non-invasive treatment option."
- "These findings further validate Apos as a viable way to delay surgery for sufferers of knee osteoarthritis, and a key solution to be added to a patient care plan."
- Avoidance of Total Knee Replacement in a Population Health Setting: Introducing a Noninvasive Biomechanical Intervention for Patients with Knee Osteoarthritis.